Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: ixhl), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Incannex Healthcare's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Incannex Healthcare's regulatory disclosures and financial reporting.
Incannex Healthcare Inc. is offering 1,997,285 shares of common stock together with accompanying Common Warrants to purchase up to 2,000,000 shares of common stock at a combined unit price of
The Common Warrants have an exercise price of
Incannex Healthcare Inc. entered into a securities purchase agreement for a registered direct offering to institutional investors. The company will sell 1,997,285 shares of common stock, pre-funded warrants for up to 2,715 additional shares, and common stock warrants to purchase up to 2,000,000 shares.
The securities are priced at a combined purchase price of $5.0 per share and accompanying warrant, or $4.9999 per pre-funded warrant and accompanying warrant, for expected gross proceeds of about $10 million before fees and expenses. The common warrants have a $6.50 exercise price and a five-year term. Warrant exercises are subject to 4.99% or, at the investor’s option, 9.99% ownership caps, and the company agreed to a 60-day restriction on issuing additional equity after closing.
Incannex Healthcare Inc. has ended its at-the-market common stock sales arrangement with Curvature Securities and A.G.P./Alliance Global Partners, which allowed it to sell shares from time to time through these agents. Over the life of this Sales Agreement, Incannex raised approximately $108.4 million in aggregate gross proceeds, and the arrangement was terminable at will by the company with no penalty.
The company also updated its corporate investor presentation, now available via its investor relations website and furnished as an exhibit, and issued a press release describing an enhanced Phase 2 dose-optimisation study, which is provided as another exhibit.
Incannex Healthcare Inc. approved and implemented a 1-for-30 reverse stock split of its common stock. Every 30 shares will be combined into 1 share at 4:01 p.m. Eastern Time on February 26, 2026, with trading on a split-adjusted basis beginning February 27, 2026.
The reverse split will reduce outstanding common shares from approximately 358,329,368 as of February 20, 2026 to about 11,944,313, without changing the total number of authorized shares or the par value. Fractional positions will be rounded up to the next whole share, with no cash paid for fractions.
The company states that the reverse split is intended to increase the per-share trading price of its stock to help regain compliance with Nasdaq’s minimum bid price requirement, while existing shareholders retain the same proportional ownership after the adjustment.
Incannex Healthcare reported no revenue for the quarter ended December 31, 2025, reflecting its status as a clinical-stage biopharmaceutical company. Net loss was $6.5 million for the quarter and $12.9 million for the six months, driven mainly by research and development and higher general and administrative expenses, including increased stock-based compensation.
Cash and cash equivalents rose sharply to $68.9 million from $15.0 million at June 30, 2025, primarily from equity issuances, partially offset by operating cash burn of $13.8 million and $1.5 million of share repurchases under a $20 million buyback program. Management believes existing cash will fund operations for at least 12 months, but the company continues to post sizable losses as it advances key programs, including its IHL-42X Phase 2/3 sleep apnea trial and other Phase 2 assets.
The company reiterates that it remains in a development phase with no product revenue and discloses an ongoing material weakness in internal control over financial reporting related to complex accounting, which it is attempting to remediate through added policies, training and control resources.
Incannex Healthcare Inc. filed a current report to note that, on January 29, 2026, it announced additional appointments to its Clinical Advisory Board. The company states that more details are provided in a press release, which is attached as Exhibit 99.1 and incorporated by reference into the filing.
Incannex Healthcare Inc. filed a current report to note a corporate development related to its PSX-001 program. On January 22, 2026, the company announced it has formed a Clinical Advisory Board to support this program, indicating a step toward organizing expert guidance around its clinical strategy. Details about the advisory board’s members, role, and expected contributions are provided in a press release dated January 22, 2026, which is attached to the report as Exhibit 99.1.
Incannex Healthcare Inc. reported the results of its 2025 Annual Meeting of Stockholders held virtually on January 15, 2026. Out of 347,705,507 shares of common stock issued and outstanding as of the October 24, 2025 record date, 119,550,295 shares, or approximately 34.38% of eligible shares, were present in person or by proxy, establishing a quorum for business.
Stockholders elected Dr. George Anastassov and Robert Clark as directors to serve until the 2028 Annual Meeting and until their successors are duly elected and qualified. Dr. Anastassov received 55,032,850 votes for and 3,295,276 votes withheld, while Robert Clark received 56,220,279 votes for and 2,107,847 votes withheld; each director election had 61,222,169 broker non-votes. Stockholders also ratified the appointment of Grant Thornton Audit Pty Ltd as the independent registered public accounting firm for the fiscal year ending June 30, 2026, with 110,346,963 votes for, 7,877,386 votes against, and 1,325,946 votes abstaining.
Incannex Healthcare Inc. reported that on January 15, 2026 it won a Research and Development Award for its obstructive sleep apnea program in the 2025 Clinical Trials Arena Excellence Awards. This recognition highlights the company’s work in developing treatments for obstructive sleep apnea.
The company also noted that additional details about the award and the program are provided in a press release, which is included as Exhibit 99.1 to this report and incorporated by reference.
Incannex Healthcare Inc. filed a current report to disclose that, on January 14, 2026, it issued a press release titled “Incannex Healthcare Inc. Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026.” The press release is attached as an exhibit and incorporated by reference, and is described as outlining the company’s 2025 progress and its well-funded outlook for 2026.